{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T10:50:28Z","timestamp":1791456628706,"version":"4.3.4"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.breast.2026.104934","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:17:14Z","timestamp":1790378234000},"page":"104934","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Analysis of outcomes of nab-paclitaxel compared to other taxanes in early breast cancer: A study revealing the critical role of calendar-time bias in real-world drug comparisons"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9972-5604","authenticated-orcid":false,"given":"Jingjing","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiling","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changjiao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4121-7532","authenticated-orcid":false,"given":"Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.breast.2026.104934_bib1","first-page":"477","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"10286","key":"10.1016\/j.breast.2026.104934_bib2","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"issue":"10384","key":"10.1016\/j.breast.2026.104934_bib3","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(23)00285-4","article-title":"Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials","volume":"401","year":"2023","journal-title":"Lancet (London, England)"},{"issue":"8","key":"10.1016\/j.breast.2026.104934_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18081733","article-title":"Taxol(\u00ae): the first microtubule stabilizing agent","volume":"18","author":"Yang","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.breast.2026.104934_bib5","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-05-1634","article-title":"Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel","volume":"12","author":"Desai","year":"2006","journal-title":"Clin Cancer Res : an official journal of the American Association for Cancer Research"},{"issue":"1","key":"10.1016\/j.breast.2026.104934_bib6","article-title":"Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.breast.2026.104934_bib7","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.21037\/apm-22-690","article-title":"Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with conventional taxanes in women with breast cancer: a systematic review and meta-analysis","volume":"11","author":"Lei","year":"2022","journal-title":"Ann Palliat Med"},{"issue":"25","key":"10.1016\/j.breast.2026.104934_bib8","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1200\/JCO.18.01842","article-title":"NAB-Paclitaxel improves disease-free survival in early breast cancer: GBG 69-GeparSepto","volume":"37","author":"Untch","year":"2019","journal-title":"J Clin Oncol : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.breast.2026.104934_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102975","article-title":"Long and short-term efficacy and safety comparison of nab-paclitaxel versus paclitaxel combined with trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer: a systematic review and meta-analysis","volume":"138","author":"Yuan","year":"2025","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"10.1016\/j.breast.2026.104934_bib10","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a041729","article-title":"Breast cancer","volume":"14","author":"Visvader","year":"2024","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.breast.2026.104934_bib11","article-title":"Novel R shiny tool for survival analysis with time-varying covariate in oncology studies: overcoming biases and enhancing Collaboration","volume":"10","author":"Li","year":"2026","journal-title":"JCO clinical cancer informatics"},{"issue":"1","key":"10.1016\/j.breast.2026.104934_bib12","article-title":"Immortal time bias in observational studies of time-to-event outcomes: assessing effects of postmastectomy radiation therapy using the national cancer database","volume":"25","author":"Agarwal","year":"2018","journal-title":"Cancer Control J Moffitt Cancer Cent"},{"issue":"1","key":"10.1016\/j.breast.2026.104934_bib13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ijrobp.2019.07.056","article-title":"Immortal time bias in national cancer database studies","volume":"106","author":"Newman","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.breast.2026.104934_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2026.1773232","article-title":"Breast cancer pathogenesis, diagnosis and treatment: a comprehensive review","volume":"16","author":"Pasi","year":"2026","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104934_bib15","doi-asserted-by":"crossref","DOI":"10.1186\/s12939-025-02390-w","article-title":"Impacts of National reimbursement drug price negotiation on drug accessibility, utilization, and cost in China: a systematic review","volume":"24","author":"Zhu","year":"2025","journal-title":"Int J Equity Health"},{"issue":"1","key":"10.1016\/j.breast.2026.104934_bib16","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1186\/s12889-021-11882-7","article-title":"Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis","volume":"21","author":"Wang","year":"2021","journal-title":"BMC Public Health"},{"key":"10.1016\/j.breast.2026.104934_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2021.714127","article-title":"Impact of the National Health insurance coverage Policy on the utilisation and accessibility of innovative anti-cancer medicines in China: an interrupted time-series Study","volume":"9","author":"Fang","year":"2021","journal-title":"Front Public Health"},{"issue":"15_suppl","key":"10.1016\/j.breast.2026.104934_bib18","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.515","article-title":"Event-free survival analysis of the prospectively randomized phase III ETNA study with neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) followed by anthracycline regimens in women with HER2-negative high-risk breast cancer","volume":"37","author":"Gianni","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.breast.2026.104934_bib19","doi-asserted-by":"crossref","DOI":"10.3892\/ol.2024.14642","article-title":"Efficacy and safety of nanoparticle albumin-bound paclitaxel compared with solvent-based paclitaxel in adjuvant therapy for breast cancer: a retrospective study","volume":"28","author":"Lv","year":"2024","journal-title":"Oncol Lett"},{"key":"10.1016\/j.breast.2026.104934_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1412051","article-title":"Pathological response and safety of albumin-bound paclitaxel as a neoadjuvant treatment for HER2-positive breast cancer compared to docetaxel combined with anti-HER2 therapy: a real-world study","volume":"14","author":"Lyu","year":"2024","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104934_bib21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2337\/dc17-1223","article-title":"Lower risk of death with SGLT2 inhibitors in observational studies: real or bias?","volume":"41","author":"Suissa","year":"2018","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.breast.2026.104934_bib22","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.chest.2018.04.006","article-title":"Observational studies of inhaled corticosteroid effectiveness in COPD: lessons learned","volume":"154","author":"Suissa","year":"2018","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.breast.2026.104934_bib23","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00376-2018","article-title":"The effect of anti-acid therapy on survival in idiopathic pulmonary fibrosis: a methodological review of observational studies","volume":"51","author":"Tran","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.breast.2026.104934_bib24","article-title":"Factors influencing delayed treatment in patients with breast cancer during COVID-19 pandemic","volume":"10","author":"He","year":"2022","journal-title":"Front Public Health"},{"issue":"13","key":"10.1016\/j.breast.2026.104934_bib25","doi-asserted-by":"crossref","first-page":"11749","DOI":"10.1007\/s00432-023-05065-7","article-title":"Therapy delay due to COVID-19 pandemic among European women with breast cancer: prevalence and associated factors","volume":"149","author":"Gremke","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"10.1016\/j.breast.2026.104934_bib26","doi-asserted-by":"crossref","first-page":"7576","DOI":"10.1097\/JS9.0000000000003266","article-title":"Impact of the COVID-19 pandemic in 2020 on the diagnosis, treatment, and prognosis of major cancers","volume":"111","author":"Tang","year":"2025","journal-title":"Int J Surg"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626002444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626002444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T09:59:23Z","timestamp":1791453563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626002444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":26,"alternative-id":["S0960977626002444"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104934","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of outcomes of nab-paclitaxel compared to other taxanes in early breast cancer: A study revealing the critical role of calendar-time bias in real-world drug comparisons","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104934","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104934"}}